CN111467481A - 一种改善和/或预防骨关节炎的组合物及其应用 - Google Patents
一种改善和/或预防骨关节炎的组合物及其应用 Download PDFInfo
- Publication number
- CN111467481A CN111467481A CN202010390429.1A CN202010390429A CN111467481A CN 111467481 A CN111467481 A CN 111467481A CN 202010390429 A CN202010390429 A CN 202010390429A CN 111467481 A CN111467481 A CN 111467481A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- powder
- improving
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 239000000843 powder Substances 0.000 claims abstract description 75
- 210000000845 cartilage Anatomy 0.000 claims abstract description 31
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims abstract description 28
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims abstract description 28
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims abstract description 27
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 25
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 25
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 25
- 235000021014 blueberries Nutrition 0.000 claims abstract description 25
- 206010034203 Pectus Carinatum Diseases 0.000 claims abstract description 24
- 239000005018 casein Substances 0.000 claims abstract description 21
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000021240 caseins Nutrition 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 21
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 21
- 235000013557 nattō Nutrition 0.000 claims abstract description 21
- 102000008186 Collagen Human genes 0.000 claims abstract description 20
- 108010035532 Collagen Proteins 0.000 claims abstract description 20
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 20
- 229920001436 collagen Polymers 0.000 claims abstract description 20
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims abstract description 18
- 229960002401 calcium lactate Drugs 0.000 claims abstract description 18
- 239000001527 calcium lactate Substances 0.000 claims abstract description 18
- 235000011086 calcium lactate Nutrition 0.000 claims abstract description 18
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 15
- 230000036541 health Effects 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims description 12
- 102000000503 Collagen Type II Human genes 0.000 claims description 9
- 108010041390 Collagen Type II Proteins 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000005786 degenerative changes Effects 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 description 26
- 239000000047 product Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 15
- 210000000988 bone and bone Anatomy 0.000 description 14
- 238000001035 drying Methods 0.000 description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 229960005069 calcium Drugs 0.000 description 11
- 239000011575 calcium Substances 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 206010003246 arthritis Diseases 0.000 description 10
- 238000004806 packaging method and process Methods 0.000 description 10
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 238000007873 sieving Methods 0.000 description 8
- 239000007779 soft material Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 6
- 229920001287 Chondroitin sulfate Polymers 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 229940059329 chondroitin sulfate Drugs 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 5
- 210000001188 articular cartilage Anatomy 0.000 description 5
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 229960005559 sulforaphane Drugs 0.000 description 5
- 235000015487 sulforaphane Nutrition 0.000 description 5
- 235000019143 vitamin K2 Nutrition 0.000 description 5
- 239000011728 vitamin K2 Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 230000008407 joint function Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 206010005963 Bone formation increased Diseases 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- -1 calcium supplements Polymers 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000006253 efflorescence Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000518 sarcolemma Anatomy 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/44—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
- A23L2/395—Dry compositions in a particular shape or form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种改善和/或预防骨关节炎的组合物及其应用,属于药物或保健品技术领域,所述组合物包括以下重量配比的组分:鸡胸软骨Ⅱ型胶原蛋白粉2‑50份、西蓝花提取物2‑20份、酪蛋白磷酸肽(CPP) 0.5份‑5份、乳酸钙1份‑10份、纳豆粉0.1份‑5份、低聚异麦芽糖10份‑80份,还包括蓝莓果汁粉0.5份‑5份。经验证,本发明的组合物能有效缓解关节疼痛,促进关节活动改善,防止关节软骨进一步退变性改变,且安全有效,为改善和预防骨关节炎提供了一种快速、有效的方案。
Description
技术领域
本发明属于药物或保健品技术领域,具体涉及一种改善和/或预防骨关节炎的组合物及其应用。
背景技术
骨关节炎(Osteoarthritis,OA)是一种较为常见的临床疾病,又称骨关节病,退行性关节病,骨质增生,肥大性关节病。随着世界范围内的人口老龄化趋势,骨关节炎患者愈来愈多。骨关节炎好发于50岁以上的中、老年人,也见于中青年等,发病率随年龄而增加,女性多见,男女之比为1:2。其中55岁以上的人群中,发病率为80%,大部分OA患者存在一定程度的运动受限,25%的OA患者日常生活受到明显影响。随着全球老龄化人口以及肥胖人口的增加,OA的患病率还将进一步提高。骨关节炎对患者关节部位造成剧烈疼痛,多累及手指关节、膝、髋、脊柱等,是影响活动的最常见原因。骨关节炎以关节软骨退变、软骨下骨硬化和骨赘形成为主要特点的关节退行性疾病,并以活动后关节疼痛、活动受限和关节变形为其主要临床表现,常累及负重关节。如手指、膝、髋、颈椎、腰椎、踝等部位。比如:手的骨关节炎,手疼痛或有手周围软组织红、肿、疼痛或压痛;不能提重物等等。诱发其他并发症,导致脊椎侧弯、关节变形、胸椎弯曲、颈椎变形;严重者会影响到心脏功能、肠道功能,并对心脑血管及高血压等多种病症产生影响。
目前,市场上上市了多种预防和缓解骨关节炎的保健食品、功能食品,例如氨基葡萄糖、硫酸软骨素、硼、软骨胶原、胶原蛋白、钙补充剂、透明质酸、姜黄等或者其组合物,但仍然存在效果不明显、口服剂量大、成本偏高、使用周期长、见效慢等问题,临床药物治疗一般以止痛药和消炎为主,用来缓解关节疼痛和炎症,这类药物虽然等短时起到一定缓解疼痛作用,但是长期使用此类药物会造成一些副作用副作用,如药物代谢造成肝损伤、胃肠道刺激症状等,非甾体抗炎药还会加重关节软骨的退化。
发明内容
本发明的目的在于提供一种用于改善或预防骨关节炎的组合物及其应用。本发明的组合物,可以同时满足骨骼及关节软骨营养需求,有助增加骨密度,促进关节软骨的修复,保持骨骼韧性和弹性,预防或减少骨关节炎、骨质疏松、骨折等情况的发生,从而提高人体关节的灵活度。
为了实现上述目的,本发明采用如下技术方案:
本发明首先提供一种用于改善或预防骨关节炎的组合物,包括以下质量百分比组分:鸡胸软骨Ⅱ型胶原蛋白粉2-50份、西蓝花提取物2-20份、酪蛋白磷酸肽(CPP)0.5份-5份、乳酸钙1份-10份、纳豆粉0.1份-5份、蓝莓果汁粉0.5份-5份、低聚异麦芽糖10份-80份。
优选的,所述组合物包括以下重量配比的成分:鸡胸软骨Ⅱ型胶原蛋白粉20-50份、西蓝花提取物11-20份、酪蛋白磷酸肽CPP 2份-5份、乳酸钙5份-10份、纳豆粉2份-20份、蓝莓果汁粉2份-5份、低聚异麦芽糖40份-80份。
进一步优选的,所述组合物包括以下重量配比的成分:鸡胸软骨Ⅱ型胶原蛋白粉20-25份、西蓝花提取物11-15份、酪蛋白磷酸肽CPP 2份-2.5份、乳酸钙5份-8份、纳豆粉2份-2.5份、蓝莓果汁粉2份-2.5份、低聚异麦芽糖40份-45份。
本发明还提供所述组合物在制备预防或改善骨关节炎的药物或保健品中的应用。
本发明还提供一种预防或改善骨关节炎的药物或保健食品,由上述的组合物结合可接受的辅料按本领域常规方法制成。所述药物组合物或保健食品的剂型可以为片剂、胶囊剂、粉剂、颗粒剂、丸剂或口服液等剂型。合适的辅料可以选自交联羧甲纤维素钠、微晶纤维素、包衣预混剂、硬脂酸镁、二氧化硅、羧甲纤维素钠、预胶化淀粉等。
本发明还提供所述组合物的制备方法,直接将所述组合物的组分混合即可。
本发明的有益效果:
(1)人体骨骼中除了钙、磷等矿物质外,还含有胶原蛋白等有机成分,这些有机成分能使骨头具有韧性和抗骨折的能力,而钙和磷等无机盐主要功能是提高骨骼的硬度,良好的骨骼应该是韧性和硬度的完美结合。而关节软骨则是由胶原蛋白、多糖等组成,中老年朋友随着年龄的增长,软骨中的各种成分例如胶原、钙、多糖等会不断流失,骨组织就会变得脆弱,因而会引起各种骨关节炎疾病,如骨质疏松、骨质增生和骨关节炎,全身骨关节疼痛、肿胀、增生等骨关节炎等退化现象。因此补充骨关节所需的营养是修复骨骼和骨关节的正常形态结构,预防骨质疏松和骨关节炎的重要环节。
(2)本发明所述的用于预防和改善骨关节炎的组合物,组合物中胶原蛋白来源为鸡胸软骨提取物,是Ⅱ型胶原能有效改善骨关节炎并减轻其疼痛;鸡胸软骨提取物还含有硫酸软骨素具有改善关节功能、减少关节肿胀和积液的功效;鸡胸软骨提取物的透明质酸具有润滑关节的作用,组合物中的西蓝花提取物能抑制炎症,L-乳酸钙是一种良好的钙源;酪蛋白磷酸肽能促进钙的吸收;纳豆粉含维生素K2具有领钙入骨的作用,组合物中低聚异麦芽糖是一种适合于中老年人的膳食纤维、组合物中蓝莓粉可以调节产品的口感和风味。
(3)本发明选用鸡胸软骨提取物(II型胶原蛋白、硫酸软骨素、透明质酸、)西蓝花提取物(萝卜硫素)、乳酸钙与酪蛋白磷酸肽CPP、纳豆粉、蓝莓粉等多种原料组合应用,经试验证明,各组分具有协同增效作用,能有效缓解关节疼痛,促进关节活动改善,防止关节软骨进一步退变性改变,且安全有效,为缓解骨关节炎或类风湿性关节炎疼痛提供了一种快速、有效的方案。
具体实施方式
为了使本领域技术人员更好的理解本发明的技术方案,下面对本发明的较佳实施例进行详细的阐述,但是如下实施例并不限制本发明的保护范围。
实施例1:
一种预防和改善骨关节炎的药物或保健品,所述药物或保健品包括以下原料,按重量份数计:鸡胸软骨Ⅱ型胶原蛋白粉50份、西蓝花提取物20份、酪蛋白磷酸肽CPP 5份、乳酸钙10份、纳豆粉5份、蓝莓果汁粉5份、低聚异麦芽糖80份。将上述原料加入到三维混合机中均匀混合得预混粉,再将混合粉直接在压片机上压片后,包装得压片糖果。
实施例2:
一种预防和改善骨关节炎的药物或保健品,所述药物或保健品包括以下原料,按重量份数计:鸡胸软骨Ⅱ型胶原蛋白粉50份、西蓝花提取物10份、酪蛋白磷酸肽CPP 2.5份、乳酸钙5份、纳豆粉2.5份、蓝莓果汁粉2份、低聚异麦芽糖45份。将上述原料加入到湿法制粒机中预先混合10min后,再加入适量水和食用酒精进行搅拌并制粒,根据制粒后颗粒松散程度添加适量水,再次搅拌后制粒干燥得软材,将软材经过16目筛,再将软材置于不锈钢盘子摊开,循环干燥箱中50℃干燥,筛取40目颗粒,包装得固体饮料。
实施例3:
一种预防和改善骨关节炎的药物或保健品,所述药物或保健品包括以下原料,按重量份数计:鸡胸软骨Ⅱ型胶原蛋白粉2份、西蓝花提取物20份、酪蛋白磷酸肽CPP 4份、乳酸钙5份、纳豆粉5份、蓝莓果汁粉5份、低聚异麦芽糖80份。将上述原料加入到三维混合机中均匀混合得预混粉,再将混合粉直接在压片机上压片后,包装得压片糖果。
实施例4:
一种预防和改善骨关节炎的药物或保健品,所述药物或保健品包括以下原料,按重量份数计:鸡胸软骨Ⅱ型胶原蛋白粉50份、西蓝花提取物2份、酪蛋白磷酸肽CPP 5份、乳酸钙8份、纳豆粉2份、蓝莓果汁粉5份、低聚异麦芽糖80份。将上述原料加入到三维混合机中均匀混合得预混粉,再将混合粉直接在压片机上压片后,包装得压片糖果。
实施例5:
一种预防和改善骨关节炎的药物或保健品,所述药物或保健品包括以下原料,按重量份数计:鸡胸软骨Ⅱ型胶原蛋白粉50份、西蓝花提取物20份、酪蛋白磷酸肽CPP 0.5份、乳酸钙1份、纳豆粉0.1份、蓝莓果汁粉5份、低聚异麦芽糖80份。将上述原料加入到湿法制粒机中预先混合10min后,再加入适量水和食用酒精进行搅拌并制粒,根据制粒后颗粒松散程度添加适量水,再次搅拌后制粒干燥得软材,将软材经过16目筛,再将软材置于不锈钢盘子摊开,循环干燥箱中50℃干燥,筛取40目颗粒,包装得固体饮料。
实施例6:
一种预防和改善骨关节炎的药物或保健品,所述药物或保健品包括以下原料,按重量份数计:鸡胸软骨Ⅱ型胶原蛋白粉50份、西蓝花提取物20份、酪蛋白磷酸肽CPP 5份、乳酸钙1份、纳豆粉0.1份、蓝莓果汁粉5份、低聚异麦芽糖80份。将上述原料加入到湿法制粒机中预先混合10min后,再加入适量水和食用酒精进行搅拌并制粒,根据制粒后颗粒松散程度添加适量水,再次搅拌后制粒干燥得软材,将软材经过16目筛,再将软材置于不锈钢盘子摊开,循环干燥箱中50℃干燥,筛取40目颗粒,包装得固体饮料。
实施例7:
一种预防和改善骨关节炎的药物或保健品,所述药物或保健品包括以下原料,按重量份数计:鸡胸软骨Ⅱ型胶原蛋白粉50份、西蓝花提取物20份、酪蛋白磷酸肽CPP 5份、乳酸钙10份、纳豆粉5份、蓝莓果汁粉0.5份、低聚异麦芽糖80份。将上述原料加入到三维混合机中均匀混合得预混粉,再将混合粉直接在压片机上压片后,包装得压片糖果。
实施例8:
一种预防和改善骨关节炎的药物或保健品,所述药物或保健品包括以下原料,按重量份数计:鸡胸软骨Ⅱ型胶原蛋白粉50份、西蓝花提取物20份、酪蛋白磷酸肽CPP 5份、乳酸钙10份、纳豆粉5份、蓝莓果汁粉0.5份、低聚异麦芽糖10份。将上述原料加入到三维混合机中均匀混合得预混粉,再将混合粉直接在压片机上压片后,包装得压片糖果。
实施例9:
一种预防和改善骨关节炎的药物或保健品,所述药物或保健品包括以下原料,按重量份数计:鸡胸软骨Ⅱ型胶原蛋白粉25份、西蓝花提取物15份、酪蛋白磷酸肽CPP 2份、乳酸钙6份、纳豆粉2.5份、蓝莓果汁粉2.5份、低聚异麦芽糖45份。将上述原料加入到三维混合机中均匀混合得预混粉,再将混合粉直接在压片机上压片后,包装得压片糖果。
实施例10:
一种预防和改善骨关节炎的药物或保健品,所述药物或保健品包括以下原料,按重量份数计:鸡胸软骨Ⅱ型胶原蛋白粉20份、西蓝花提取物11份、酪蛋白磷酸肽CPP 3份、乳酸钙5份、纳豆粉2.5份、蓝莓果汁粉3份、低聚异麦芽糖40份。将上述原料加入到湿法制粒机中预先混合10min后,再加入适量水和食用酒精进行搅拌并制粒,根据制粒后颗粒松散程度添加适量水,再次搅拌后制粒干燥得软材,将软材经过16目筛,再将软材置于不锈钢盘子摊开,循环干燥箱中50℃干燥,筛取40目颗粒,包装得固体饮料。
在本发明中,各组分的选取,是经过大量试验的验证,得到的具有突出的实质性特点和显著的进步的组合物,在药物或保健品中,原料配伍是非常重要的,任何一种原料或组分的用量、选择是否添加都是对疗效有直接的影响。本发明中,
鸡胸软骨Ⅱ型胶原蛋白粉:胶原蛋白是细动物体内分布最广、含量最多的蛋白质,是结缔组织的重要成分之一。Ⅱ型胶原主要分布在软骨、髓核和玻璃体中,Ⅱ型胶原主要存在于软骨基质,占软骨干重的一半以上,具有很好的免疫调节功效。此外,胶原蛋白还能强化肌肤韧性,延缓肌体衰老,是补钙、美容护肤、延缓衰老类保健食品的理想材料。本发明所采用的鸡胸软骨Ⅱ型胶原蛋白粉按照常规公开方法由鸡胸软骨提取而成,还含有约30份硫酸软骨素、10份透明质酸(以质量计)。
硫酸软骨素(chondroitin sulfate,CS,以下简称CS)是一类硫酸化的糖胺聚糖,存在于人和动物结缔组织中,主要分布于软骨、骨、肌腱、肌膜和血管壁中,成本低、长期服用胃肠耐受性更好、无毒副作用。
透明质酸(HA)是构成关节软骨和滑液的主要成分,透明质酸是一种酸性粘多糖,以其独特的分子结构和理化性质在机体内显示出多种重要的生理功能,如润滑关节,调节血管壁的通透性,调节蛋白质,水电解质扩散及运转,促进创伤愈合等。
西兰花也就是花椰菜、绿花菜、青花菜,是一种草本植物,其可食部为其冠状的花朵,因其营养价值及其丰富,被誉为“蔬菜皇冠”,西蓝花提取物按照常规公开方法提起,其富含萝卜硫素,萝卜硫素是十字花科蔬菜中富含的一种化合物,如球芽甘蓝、卷心菜,都含有丰富的萝卜硫素,而西兰花则是萝卜硫素含量最丰富的一种蔬菜。
L-乳酸钙外观为白色无味的粉末或颗粒,以淀粉为原料经天然发酵制成。具有微风化性和抗氧化性,由于其具有呈中性、易溶解、口感好、易吸收、对肠道无不良反应等优点,L-乳酸钙是一种良好的钙源。
酪蛋白磷酸肽(CPP)是从牛乳酪蛋白通过生物技术制得的一种新型功能性食品添加剂。CPP是有磷酸基的肽,它具有促进人体吸收钙的生理活性。
纳豆,源自中国,由黄豆通过纳豆菌(枯草杆菌)发酵制成的豆制品,不仅保有黄豆的营养价值、富含维生素K2、提高蛋白质的消化吸收率,更重要的是发酵过程产生了多种生理活性物质,具有溶解血栓、防止骨质疏松及其他调节生理机能的保健作用。纳豆粉中包含大豆异黄酮和维生素K2,大豆异黄酮能防止骨中钙的溶解,而维生素K2则能够将钙固定于骨中,两者相互协力,起到强骨的作用。
低聚异麦芽糖(Isomaltooligosaccharide,IMO)是一种具有良好生理功能的益生元。它是以精制玉米淀粉为原料,经酶法水解、转苷而成的一种新型功能性淀粉糖,也是一种水溶性膳食纤维。低聚异麦芽糖发酵成短链脂肪酸可酸化肠道环境,刺激肠道蠕动、增加粪便湿润度并保持一定的渗透压,从而防治便秘的产生,并能促进其对钙等矿物质的吸收。
蓝莓粉是精选国内无公害蓝莓为原料,采用低温冷萃加低温浓缩干燥而成。保持了蓝莓原有的各种营养、保健成份和原料的天然本色,广泛应用于加工各种蓝莓风味食品和添加于各类营养食品中,以强化其营养保健功效,并赋予各类食品天然蓝莓颜色和特有的蓝莓风味。
本发明还包括可接受的辅料按本领域常规方法制成不同剂型,所制备得到的药物或保健食品的剂型可以为片剂、胶囊剂、粉剂、颗粒剂、丸剂或口服液等剂型,辅料可选自交联羧甲纤维素钠、微晶纤维素、包衣预混剂、硬脂酸镁、二氧化硅、羧甲纤维素钠、预胶化淀粉等。
为了进一步验证本发明组合物制备得到的药物或保健品在预防或治疗骨关节炎中的效果,本发明同时进行了一些对比实验进行验证。
分别设置对比例如下:
表1:各对比组药物或保健品成分及含量
试验例1:本发明的组合物在减轻关节炎造成的关节疼痛方面的作用
将雄性wistar大鼠(购自上海斯莱克实验动物有限责任公司)随机分为对照组、模型组、实验组,每组12只,同期给药28天。
根据小鼠体重计算灌胃用量,具体的每组处理方法如下:
对照组:灌胃生理盐水。
模型组:通过木瓜蛋白酶注射造模,造模后灌胃生理盐水。
实验组:实施例1-10以及7个对比组所述的药物或保健品组分按照和相同的料水比例混合得到水溶液进行灌胃。
处死前压痛仪测量造模关节部位压痛阈值,具体结果如表2所示:
表2:各组大鼠压痛阈值结果
从表2可见,对照组正常大鼠因未患关节炎,其关节在被按压时候承受的压力更大,模型组大鼠因患关节炎但未接受治疗,对疼痛的敏感度更高,按压时承受的力小,给药喂养本发明实施例1-10产品可以较好的缓解关节炎,在按压时所能承受的力相比模型组更大。
同时,从表2中数据可以得出,与对比组1-7相比较,采用本发明实施例1-10的产品灌胃的大鼠所能承受的力大于对比组1-7产品灌胃的大鼠,充分证明本发明的组合物具有更好的缓解关节炎疼痛的作用。
试验例2:本发明的组合物预防或改善骨关节炎指数方面的作用
按照本发明实施例1-10以及对比组1-7的组合物组分及含量,按照常规公知方法制备压片糖果。
试验对象:选取年龄30-70岁膝关节炎患者且无其他病症的自愿者,分成17组,每组8人。
试验方法:试验对象每人每天服用一片本发明实施例1-10以及对比组1-7所涉及组分及含量制备的压片糖果,连续服用8周,分别于服用前、服用2周、4周、8周后进行关节功能测试,采用WOMAC关节炎指数(使用VAS尺度,1-10cm)结果进行分析。
表3.各组实验对象关节炎指数测试结果
将受试对象在服用前、服用2周、4周、8周后进行关节功能测试结果进行统计分析,p<0.05。由表3可见,与服用其他关节炎药物实验组患者相比,关节炎患者在服用本发明的组合物4周后,关节炎指数明显下降,在8周后,效果更为明显。
Claims (10)
1.一种改善和/或预防骨关节炎的组合物,其特征在于,所述组合物按重量份计,包括:鸡胸软骨Ⅱ型胶原蛋白粉2-50份、西蓝花提取物2-20份、酪蛋白磷酸肽CPP 0.5份-5份、乳酸钙1份-10份、纳豆粉 0.1份-5份、低聚异麦芽糖10份-80份。
2.根据权利要求1所述的一种改善和/或预防骨关节炎的组合物,其特征在于,所述组合物按重量份计,包括:鸡胸软骨Ⅱ型胶原蛋白粉20-50份、西蓝花提取物11-20 份、酪蛋白磷酸肽CPP 2份-5份、乳酸钙5份-10份、纳豆粉 2份-20份、低聚异麦芽糖40份-80份。
3.根据权利要求2所述的一种改善和/或预防骨关节炎的组合物,其特征在于,所述组合物按重量份计,包括:鸡胸软骨Ⅱ型胶原蛋白粉20-25份、西蓝花提取物11-15 份、酪蛋白磷酸肽CPP 2份-2.5份、乳酸钙5份-8份、纳豆粉 2份-2.5份、低聚异麦芽糖40份-45份。
4.根据权利要求1-3任一项所述的一种改善和/或预防骨关节炎的组合物,其特征在于,所述组合物还包括蓝莓果汁粉 0.5 份-5份,优选2份-5份,更优选2份-2.5份。
5.权利要求1-4任一项所述的一种改善和/或预防骨关节炎的组合物在制备改善、预防或治疗骨关节炎药物或保健品中的应用。
6.根据权利要求5所述的应用,其特征在于,所述应用为将权利要求1-3任一项所述的组合物结合敷料制备成可接受的剂型。
7.根据权利要求6所述的应用,其特征在于,所述剂型为口服制剂。
8.根据权利要求7所述的应用,其特征在于,所述口服制剂剂型为片剂、胶囊剂、粉剂、颗粒剂、丸剂或口服液。
9.根据权利要求6所述的应用,其特征在于,所述辅料选自交联羧甲纤维素钠、微晶纤维素、包衣预混剂、硬脂酸镁、二氧化硅、羧甲纤维素钠、预胶化淀粉。
10.一种改善、预防或治疗骨关节炎的药物或保健品,其特征在于,所述药物或保健品包含权利要求1-4任一项所述的组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010390429.1A CN111467481A (zh) | 2020-05-08 | 2020-05-08 | 一种改善和/或预防骨关节炎的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010390429.1A CN111467481A (zh) | 2020-05-08 | 2020-05-08 | 一种改善和/或预防骨关节炎的组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111467481A true CN111467481A (zh) | 2020-07-31 |
Family
ID=71762250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010390429.1A Pending CN111467481A (zh) | 2020-05-08 | 2020-05-08 | 一种改善和/或预防骨关节炎的组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111467481A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112675295A (zh) * | 2020-12-10 | 2021-04-20 | 浙江蓝美生物技术有限公司 | 一种可预防与改善骨关节炎症的蓝莓粉复方固体制剂及其制备方法和应用 |
CN113230381A (zh) * | 2021-06-01 | 2021-08-10 | 杭州丽昌农业科技有限公司 | 一种增加骨密度的配方 |
CN114601920A (zh) * | 2022-03-23 | 2022-06-10 | 宁波御坊堂生物科技有限公司 | 一种用于改善骨关节健康的口服脂质体组合物及其制备方法 |
CN115282248A (zh) * | 2022-08-15 | 2022-11-04 | 北京彩晔健康管理有限公司 | 一种缓解关节疼痛或治疗关节炎的组合物、及其制备方法与用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101785547A (zh) * | 2010-03-19 | 2010-07-28 | 许勇男 | 纳豆纳米钙咀嚼片 |
CN108112997A (zh) * | 2017-12-18 | 2018-06-05 | 北京康比特体育科技股份有限公司 | 一种保健食品组合物 |
CN108378374A (zh) * | 2018-02-08 | 2018-08-10 | 湖南易能生物医药有限公司 | 一种预防骨质疏松、促进骨健康的组合物 |
CN109288064A (zh) * | 2018-10-10 | 2019-02-01 | 宝健(北京)生物技术有限公司 | 一种维生素k组合物、包括其的钙平衡制剂及应用 |
CN109769947A (zh) * | 2017-11-15 | 2019-05-21 | 内蒙古伊利实业集团股份有限公司 | 一种改善骨健康功能性组合物及其产品和应用 |
-
2020
- 2020-05-08 CN CN202010390429.1A patent/CN111467481A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101785547A (zh) * | 2010-03-19 | 2010-07-28 | 许勇男 | 纳豆纳米钙咀嚼片 |
CN109769947A (zh) * | 2017-11-15 | 2019-05-21 | 内蒙古伊利实业集团股份有限公司 | 一种改善骨健康功能性组合物及其产品和应用 |
CN108112997A (zh) * | 2017-12-18 | 2018-06-05 | 北京康比特体育科技股份有限公司 | 一种保健食品组合物 |
CN108378374A (zh) * | 2018-02-08 | 2018-08-10 | 湖南易能生物医药有限公司 | 一种预防骨质疏松、促进骨健康的组合物 |
CN109288064A (zh) * | 2018-10-10 | 2019-02-01 | 宝健(北京)生物技术有限公司 | 一种维生素k组合物、包括其的钙平衡制剂及应用 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112675295A (zh) * | 2020-12-10 | 2021-04-20 | 浙江蓝美生物技术有限公司 | 一种可预防与改善骨关节炎症的蓝莓粉复方固体制剂及其制备方法和应用 |
CN113230381A (zh) * | 2021-06-01 | 2021-08-10 | 杭州丽昌农业科技有限公司 | 一种增加骨密度的配方 |
CN114601920A (zh) * | 2022-03-23 | 2022-06-10 | 宁波御坊堂生物科技有限公司 | 一种用于改善骨关节健康的口服脂质体组合物及其制备方法 |
CN115282248A (zh) * | 2022-08-15 | 2022-11-04 | 北京彩晔健康管理有限公司 | 一种缓解关节疼痛或治疗关节炎的组合物、及其制备方法与用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111467481A (zh) | 一种改善和/或预防骨关节炎的组合物及其应用 | |
CN101248882B (zh) | 一种具有促进骨骼和骨关节健康的营养食品 | |
CN106135890A (zh) | 一种有助于骨关节健康的营养组合物 | |
CN103736074B (zh) | 一种增加骨密度保健胶囊及其制备方法 | |
CN102150836A (zh) | 氨糖多肽软胶囊 | |
CN102423487B (zh) | 一种骨关节保健组合物及其应用 | |
CN102949710B (zh) | 增加骨密度的药物组合物或保健品及其制备方法 | |
CN102178934B (zh) | 一种用于增加骨密度、防治骨关节病及增强免疫力的制剂 | |
CN106235311A (zh) | 一种促进骨骼系统健康的组合物及其应用 | |
CN101049157B (zh) | 一种具有预防骨质疏松作用的保健食品 | |
CN101711786B (zh) | 一种用于缓解骨关节病、增强免疫力的制剂 | |
CN101181294A (zh) | 一种用于治疗骨性关节炎的药物组合物 | |
CN108783467B (zh) | 改善骨质疏松和增加骨密度的组合物及其制备方法 | |
CN105124347A (zh) | 一种辣木降血糖组合物及其制备方法 | |
KR101513855B1 (ko) | 알긴산을 포함하는 골관절염 예방 또는 치료용 조성물 | |
CN101455396A (zh) | 一种促进骨和骨关节健康的营养保健食品 | |
CN104824677A (zh) | 一种增加骨密度的保健食品及其制备方法 | |
CN114365850A (zh) | 一种具有改善软骨健康的多肽组合物及其制备方法 | |
CN109464651A (zh) | 一种软骨代谢异常疾病改善用健康食品及药品组合物 | |
JP2007099653A (ja) | 関節痛改善剤 | |
CN114698850A (zh) | 一种蛋膜肽组合物的配方及制作方法 | |
CN108815505A (zh) | 提高中老年人骨密度和骨关节功能避免腰腿抽筋的组合物 | |
CN114617267A (zh) | 一种强化型复合骨肽及其制备方法与应用 | |
CN103238839A (zh) | 用于保养关节的含胶原蛋白的食品组成物 | |
AU2019101234B4 (en) | Formulation and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |